IPS HEART
  • Home
  • About Us
  • Our Approach
  • Our Pipeline
  • Why Heart Disease?
  • Why DMD?
  • Platform
  • Publications
  • Clinical Efficacy
  • More
    • Home
    • About Us
    • Our Approach
    • Our Pipeline
    • Why Heart Disease?
    • Why DMD?
    • Platform
    • Publications
    • Clinical Efficacy
IPS HEART
  • Home
  • About Us
  • Our Approach
  • Our Pipeline
  • Why Heart Disease?
  • Why DMD?
  • Platform
  • Publications
  • Clinical Efficacy

FEATURED MANUSCRIPTS

Cardiac Progenitors Induced from Human Induced Pluripotent Stem Cells with Cardiogenic Small Molecule Effectively Regenerate Infarcted Hearts

miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart

miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart

Cardiac progenitor cells (CPCs) being multipotent offer a promising source for cardiac repair due to their ability to proliferate and multiply into cardiac lineage cells. Here, we explored a novel strategy for human CPCs generation from human induced pluripotent stem cells (hiPSCs) using a cardiogenic small molecule, isoxazole (ISX-9) and

Cardiac progenitor cells (CPCs) being multipotent offer a promising source for cardiac repair due to their ability to proliferate and multiply into cardiac lineage cells. Here, we explored a novel strategy for human CPCs generation from human induced pluripotent stem cells (hiPSCs) using a cardiogenic small molecule, isoxazole (ISX-9) and their ability to grow in the scar tissue for functional improvement in the infarcted myocardium.

Read more

miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart

miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart

miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart

Cardiac stem cell therapy offers the potential to ameliorate postinfarction remodeling and development of heart failure but requires optimization of cell-based approaches. Cardiac progenitor cells (CPCs) induction by ISX-9, a small molecule possessing antioxidant, prosurvival, and regenerative properties, represents an attractive potentia

Cardiac stem cell therapy offers the potential to ameliorate postinfarction remodeling and development of heart failure but requires optimization of cell-based approaches. Cardiac progenitor cells (CPCs) induction by ISX-9, a small molecule possessing antioxidant, prosurvival, and regenerative properties, represents an attractive potential approach for cell-based cardiac regenerative therapy. Here, we report that extracellular vesicles (EV) secreted by ISX-9-induced CPCs (EV-CPCISX-9) faithfully recapitulate the beneficial effects of their parent CPCs with regard to postinfarction remodeling. 

Read more

Pluripotent stem cell-induced skeletal muscle progenitor cells with givinostat promote myoangiogenesis

miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart

Pluripotent stem cell-induced skeletal muscle progenitor cells with givinostat promote myoangiogenesis

Duchenne muscular dystrophy (DMD) is caused by mutations of the gene that encodes the protein dystrophin. A loss of dystrophin leads to severe and progressive muscle wasting in both skeletal and heart muscles. Human induced pluripotent stem cells (hiPSCs) and their derivatives offer important opportunities to treat a number of diseases. H

Duchenne muscular dystrophy (DMD) is caused by mutations of the gene that encodes the protein dystrophin. A loss of dystrophin leads to severe and progressive muscle wasting in both skeletal and heart muscles. Human induced pluripotent stem cells (hiPSCs) and their derivatives offer important opportunities to treat a number of diseases. Here, we investigated whether givinostat (Givi), a histone deacetylase inhibitor, with muscle differentiation properties could reprogram hiPSCs into muscle progenitor cells (MPC) for DMD treatment. 

Read more

Media & Press

GIVI-MPC earns FDA orphan drug designation to treat DMD.

IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD

IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD

Source: Muscular Dystrophy News         

Read more

IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD

IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD

IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD

Source: Muscular Dystrophy News         

Read more

IPS HEART Aims to Use Induced Pluripotent Stem Cells to Treat Heart Attack

IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD

FDA Grants Rare Pediatric Drug Designation for IPS Heart’s Stem Cell Therapy to Treat Cardiomyopathy Due to Danon Disease

Source: Biobanking

Read more

FDA Grants Rare Pediatric Drug Designation for IPS Heart’s Stem Cell Therapy to Treat Cardiomyopathy Due to Danon Disease

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate

FDA Grants Rare Pediatric Drug Designation for IPS Heart’s Stem Cell Therapy to Treat Cardiomyopathy Due to Danon Disease

Source: Global Genes, RARE Daily

Read more

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate

Source: Businesswire

Read more

IPS HEART receives FDA Rare Pediatric Drug Designations for both of its Stem Cell Drugs for Duchenne Muscular Dystrophy

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate

IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate

Source: Businesswire

Read more

FDA grants IPS HEART Orphan Drug Designation for GIVI-MPC for Treatment of Duchenne Muscular Dystrophy

Source: Businesswire

Read more

IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapy’s Ability to Create New Skeletal Muscle in Aged Mice

Source: Businesswire

Read more

IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy

IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy

Source: Businesswire

Read more

Copyright © 2014 IPS HEART - All Rights Reserved.